Objective: To determine whether diet supplementation with arabinoxylan-rich (AX)-fibre from wheat improves glycaemic control in Type II diabetes. Design: Randomized, crossover intervention trial. Setting: Monash Medical Centre. Subjects: A total of 15 subjects with Type II diabetes. Interventions: Over two 5-week periods, subjects supplemented their usual diet with control bread and muffins (50% whole wheat, 50% white flour) (control diet) or with AX-bread and muffins (50% whole wheat, 36% white flour, 14% AX fibre) (AX diet). Subjects completed a 7-day food diary. At 0 and 5 weeks, venous blood was collected for determination of fasting and 2 h glucose, insulin, fructosamine and blood lipids. Blood pressure, body weight and body fat were also determined. A 24 h faecal sample, from 12 subjects, was weighed and analysed for faecal polysaccharide as a marker for dietary compliance. Results: Control and AX diets were similar except the AX diet supplied an additional 15.1 (12.0-18.5) (mean (95% confidence intervals)) g/day dietary fibre (P ¼ 0.000). Consumption of the AX diet increased faecal output by 61.5 (0.2-122.8) g/day (P ¼ 0.05) on a wet weight basis and significantly lowered fasting and 2 h plasma glucose, 2 h insulin and serum fructosamine (P ¼ 0.002, 0.000, 0.015, and 0.02, respectively). Blood lipids, body weight, fat mass and blood pressure remained unchanged. Conclusion: A supplement of 15 g/day of AX-rich fibre can significantly improve glycaemic control in people with Type II diabetes.
Introduction
Type II diabetes is an increasingly common disease in Western countries (Dunstan et al, 2001) . Associated medical and societal costs are considerable (Brown et al, 1999a) . Long-term hyperglycaemia promotes development of coronary heart disease, a major cause of death (Donnelly & Davis, 2000) as well as microvascular complications leading to neuropathy, kidney and eye disease (Cooper et al, 2001) . Normalization of blood glucose is therefore an important goal in the medical nutrition therapy of Type II diabetes (Franz et al, 2002) . The diet most widely recommended for treatment of Type II diabetes (Lean et al, 1991) is low in total fat to aid weight loss and to improve plasma lipids (Walker et al, 1995; Storm et al, 1997; Heilbronn et al, 1999) and high in fibre-rich carbohydrate.
Diets high in fibre-rich carbohydrate can improve blood glucose and insulin concentrations as well as contributing to blood lipid lowering in people with Type II diabetes (Chandalia et al, 2000) . However, the levels of fibre required to induce these beneficial effects are high (up to 50 g/day) (Franz et al, 2002) and difficult for people accustomed to Western diets to achieve (Alaimo et al, 1994) . For this reason, the effects of purified soluble fibre supplements including guar gum (Groop et al, 1993) , beta-glucan (Wursch & PiSunyer, 1997) , konjac-mannan (Vuksan et al, 1999) and psyllium (Anderson et al, 1999) have been explored. In this study, we examine the effects of arabinoxylan-rich (AX) fibre, because of its particular acceptability and palatability (Lu et al, 2000a) as a potentially even more useful fibre supplement for people with Type II diabetes.
AX is a major fibre component in many cereal grains (Henry, 1985) . It is a hemicellulose that has a xylose backbone with arabinose side chains (Amodo & Neukom, 1985) . Here, we have used an AX-rich fibre extracted as a byproduct from wheat flour processing (Lu et al, 2000a) . This fibre product is rich in nonstarch polysaccharides (NSP) (70% by weight), with a ratio of soluble to insoluble NSP of 1.6 (Lu et al, 2000a) . We have shown in animals that this wheatderived AX fibre behaves in the bowel as a soluble, viscous fibre, similar to guar gum (Lu et al, 2000b) . Moreover, small quantities added to a test meal significantly lowered postprandial glucose and insulin responses in an acute study in healthy volunteers (Lu et al, 2000a) . Now we examine the longer term effects on glycaemic control in people with Type II diabetes.
Methods

Subjects
Volunteers for the study were recruited from the Brunswick Community Health Centre, Melbourne, Australia. A total of 15 subjects (nine female, six male) with Type II diabetes completed the study, which was approved by the Standing Committee on Ethics in Research on Humans, Monash University, Victoria, Australia. All subjects gave their written informed consent. Eight of the nine women were postmenopausal. Subjects were aged (mean7s.e.m.) 6072 y, with a body mass index of 28.170.9 kg/m 2 and had been diagnosed with Type II diabetes for 2.370.6 y. For treatment of their diabetes, 10 subjects depended on diet therapy alone and five were taking low-dose oral hypoglycaemic agents. None required insulin. Two subjects took lipid-lowering medications and nine took antihypertensive agents. All medication continued without change throughout the study. All subjects had sedentary lifestyles and were asked to maintain their habitual physical activity throughout the study.
Diet and diet supplements
During both the control and test diets, subjects followed their habitual diet but replaced the majority of their starchy foods with specified quantities of control or AX-fibreenriched bread and muffins. Control bread and muffins were made with 50% whole-wheat and 50% white flour. AX bread and muffins were made with 50% whole-wheat, 36% white flour and 14% AX-rich fibre. The AX-rich fibre contained no fat, and little protein (10% weight/weight) or starch (15%). It comprised mainly of NSP (70%) particularly soluble NSP (ratio soluble: total NSP, 0.62). All bread and muffins were prepared to standard recipes by a professional baker who ensured that control and test breads presented with similar flavour, colour and texture (Lu et al, 2000a) . Subjects were required to eat 4-5 slices of bread and 1-2 muffins per day depending on energy requirements. During the AX diet, each subject therefore received a supplement of 14-17 g of NSP per day from AX-rich foods.
Experimental design
The study was based on a randomized crossover design where free-living subjects followed a control diet and an AX diet, each for 5 weeks. Seven subjects started the AX diet first, while eight subjects started the control diet first. Subjects were assessed at the beginning and the end of each dietary period. Of the 15 subjects, 14 had a total of three assessments with no washout period between diets. One subject, however, was assessed on four occasions (before and after each diet) since in this case only, an interval of 4 months occurred between diets. Subjects but not researchers were blind to the type of diet followed. For each assessment, subjects came in to the laboratory after an overnight fast. Venous blood samples were collected during the fasting state and 2 h after a 75 g oral glucose tolerance test (OGTT). Blood pressure, total body weight and body fat mass were also determined. At the end of each diet, subjects completed questionnaires concerning their acceptance of the dietary supplements and their bowel symptoms. A 24 h faecal sample was collected during the last 3 days of each diet from 12 of 15 subjects. Subjects completed a 7-day food diary based on household measures in the last week of each dietary period. Each subject received a set of standard measuring cups and spoons and detailed instructions for recording food intakes. The 7-day dietary records were analysed using Diet 4 (Xyris Software, Queensland, Australia), based on the Australian Nutrient Composition database NUTTAB95 and nutrient intakes were reported as an average over 7 days.
Assessment of compliance Dietary compliance was assessed by self-report using questionnaires and by faecal analysis. At the end of each diet, subjects were asked to rate their response to the bread or muffins on a structured scale with nine categories: 'like extremely' (score ¼ 1) to 'dislike extremely' (score ¼ 9) (Land & Shepherd, 1988) . Subjects were also asked to indicate how often they had consumed the bread and muffins supplied to them. Five phrases (bread and muffins eaten 0, 25, 50, 75 and 100% of the time) were used and responses were rated on a score from 1 (0% of the time) to 5 (100% of the time).
At the end of each diet, subjects were asked to score the daily frequency of their bowel movements on a scale in nine categories ranging from 1 ¼ 'much less than usual', 5 ¼ 'usual', and 9 ¼ 'much greater than usual'. In this questionnaire, subjects were also asked to score for side effects relating to high fibre intake. Faecal weight and daily excretion of polysaccharides (ie the sum of faecal nonstarch polysaccharides and resistant starch) were used as additional biological markers for dietary compliance. At the end of each diet, preweighed containers were used to collect each defaecation made over a 24 h period. These were immediately placed on solid carbon dioxide (dry-ice) and transported in an insulated container to the laboratory for storage at À701C. Before analysis, faeces from each subject were weighed, thawed at 301C for 30 min, combined and mixed thoroughly using a hand-held electric blender. Aliquots were transferred into tubes and faecal moisture content was determined after freeze-drying to a constant weight. Freezedried samples were ground to a powder with a mortar and pestle and stored desiccated at À401C.
Total body weight and fat mass Subjects were weighed and scanned while clothed in a light cotton gown and after the removal of shoes and all metal objects. Total body weight was measured to the nearest 0.1 kg on a digital scale (Model 708, Seca Hamburg, Germany). Total fat mass was assessed from a whole body bone densitometry scan (DPX-L; Lunar Corporation, Madison, WI, USA) following procedures described previously (Walker et al, 1996) .
Biochemical analyses
Fasting blood samples were analysed for glucose, insulin, fructosamine, total cholesterol, high-density lipoprotein (HDL)-cholesterol and triacylglycerol, while 2 h blood samples were analysed for glucose and insulin. Blood was collected into a sodium fluoride ethylene-diaminetetraacetic acid (EDTA) vacuette s tube (Greiner Labortechnik, Kremsmünster, Austria) for the analysis of glucose in the plasma and into a vacuette s tube containing a serum clot activator (Greiner Labortechnik) for the analysis of serum insulin, lipids and fructosamine. Blood analyses were undertaken by the Department of Chemical Pathology, Monash Medical Center, Melbourne, Australia. Plasma glucose was measured in duplicate by the hexokinase method using an automatic analyzer (Dimension s Autoanalyzer, Dade International Inc., Newark, DE, USA) and commercially available colorimetric reagents (Dade International Inc.). The interassay coefficient of variation (CV) was 3.2% at 7.21 mmol/l and 2.9% at 13.97 mmol/l. Serum insulin was determined by the Microparticle Enzyme Immunoassay (MEIA) on an automatic analyzer (AxSYM s , Abbott GmbH Diagnostika, Wiesbaden-Delkenheim, Deutschland) using AxSYM s reagents (Abbot). Interassay CVs were 4.3% at 62 pmol/l and 4.0% at 905 pmol/l. Serum total cholesterol and triacylglycerol concentrations were assayed on a Dimension s Autoanalyser using enzymatic colorimetric reagents (Dade International Inc.). The interassay CV was 4.1% at 4.19 mmol/l and 3.1% at 7.67 mmol/l for serum cholesterol and 3.7% at 1.69 mmol/l and 2.5% at 4.53 mmol/l for serum triacylglycerol. Serum HDL-cholesterol concentration was assayed similarly after precipitation of other lipoproteins (Boehringer-Mannheim Systems Reagent Kit, Boehringer Mannheim GmbH Diagnostica, Mannheim, Germany). The interassay CV was 4.9% at 0.93 mmol/l. LDL-cholesterol was calculated using the Friedewald equation (Friedewald et al, 1972) . Fructosamine was analysed in serum following methods described by Johnson et al (1983) and using an automated analyser (Roche COBAS BIO, Basle, Switzerland) and Roche Fructosamine Unimate reagents. The intra-assay CV was 0.6% (n ¼ 6) at a concentration of 231 mmol/l.
Faecal polysaccharide content was determined according to Englyst et al (1994) except that analysis started with acid hydrolysis of the freeze-dried faecal sample and in vitro digestion steps with enzymes to remove starch were omitted because digestible starch is removed during passage through the gut. A spectrophotometer (Spectronic 1201, Milton Roy, USA) was used to measure released sugars colorimetrically at 530 nm against a glucose standard curve.
Statistical analysis
Data are expressed as the mean7s.e.m. A value of Po0.05 was considered of statistical significance. All analyses were performed using the statistical software package SPSS 10.0 for Windows (SPSS Inc., Chicago, IL, USA). Comparison of nutrient intakes on the control and AX diets and of all the faecal parameters was undertaken using a two-tailed paired Student's t-test. This test was also used for comparisons of parameters at the beginning (week 0) and end (week 5) of each diet.
Differences between the two arms of the crossover study were evaluated using a general linear model (GLM) for crossover design (Fleiss, 1996) after it had been demonstrated that the sequence of diet administered had no effect on outcome variables. Briefly, the difference between 'before' and 'after' each diet for each measurement was used as a dependent variable. The type of diet, sequence of diet administered and the individual difference (subject identification number) were entered as independent factors in the computation to derive an appropriate estimate of random error.
Differences in responses to questionnaires were analysed using Wilcoxon's signed ranks, a nonparametric test for paired samples. These data are expressed as the median, with the 25th and 75th percentile of the median given in parentheses.
Results
Before commencing the study, subjects as a group exhibited good diabetic control (HbA 1c 6.370.2%, fasting and 2 h glucose 7.570.3 and 15.170.9 mmol/l, respectively). They were also normolipidaemic (total cholesterol 5.4370.23 mmol/l, total triacylglycerol 1.8070.28 mmol/l) and normotensive (systolic and diastolic blood pressure 14474 and 7672 mmHg, respectively). Seven subjects started the AX diet first, while eight subjects started the control diet first. The order in which diets were administered was found not to affect any of the measured variables.
Dietary intake
Nutrient intake for the subjects during control and test diets is shown in Table 1 . The control diet was similar to the AX diet for all nutrients except dietary fibre. On the AX diet, dietary fibre intake was 4972 g/day (2471 g/1000 kcal) compared to 3472 g/day (1671 g/1000 kcal) during the control diet, a difference of 15 g/day (Po0.001).
Dietary compliance
Subjects reported no difficulty in following the two diets. They expressed no dislike for their supplements of bread and muffins. Median scores (25th percentile, 75th percentile) reporting acceptance of control and AX breads were very similar (5 (4-6) and 5 (3-7), respectively, P ¼ 0.63) as were acceptance scores for control and AX muffins (5 (3-6) and 4 (3-6), respectively, P ¼ 0.89).
When subjects were asked whether they had eaten all the bread and muffin supplements supplied to them each day, consumption patterns did not differ between control and AX-rich foods (median score 5 (4-5) in each case). During the control diet, nine of 15 subjects reported that they had eaten all supplements supplied throughout the study, while six subjects reported eating the required amount more than 75% of the time. During the AX diet, 11 subjects reported that they had eaten all their supplements throughout the study, while four subjects said that they had eaten them more than 75% of the time.
On the AX diet, subjects reported more bowel movements per day than on the control diet (score 7 (5-8) vs 5 (5-7) (median (25th-75th percentile), AX diet and control diet respectively, Po0.05). Figure 1 indicates the daily faecal output (wet weight) and faecal polysaccharide content after each diet for 12 of the 15 subjects. On the AX diet, mean faecal output was significantly higher than after the control diet (284736 and 223730 g/day, respectively, P ¼ 0.05). On a dry weight basis, mean faecal output tended to be higher (6377 and 5377 g/day, respectively, P ¼ 0.06). In addition, the polysaccharide (ie NSP þ RS) content of the faeces was significantly higher after the AX diet (15.172.9 and 17.372.8 g/day, control and AX diet, respectively, P ¼ 0.02).
Assessment of abdominal symptoms
Analysis of subjects' reports revealed no significant difference in flatulence, abdominal distension or cramping between the AX and control diets (data not shown). No incidence of diarrhoea was reported on either diet.
Changes in glycaemic control
The AX-rich diet improved glycaemic control (Table 2 and Figure 2 ). There was no difference at week 0 between the control and AX diets in regard to either fasting or 2 h blood glucose and insulin concentrations (Table 2) . On the AX diet fasting plasma glucose concentrations fell by 0.670.2 mmol/ l (P ¼ 0.002), whereas levels remained stable during the control diet. Fasting plasma glucose was thus significantly lower (Po0.05) on the AX diet than on the control diet (Figure 2a ).
Similar and even more marked responses were seen with 2 h blood glucose concentrations. At week 5, after the AX diet, 2 h plasma glucose was 1.870.4 mmol/l lower than at week 0 (Po0.001), whereas after the control diet the change in 2 h glucose remained insignificant (P ¼ 0.3). The between- diet difference was thus highly significant (Po0.001) (Figure 2a ). There was no difference between diets in the levels of fasting serum insulin. After the AX diet, however, the 2 h post-OGTT serum insulin had decreased by 163760 pmol/l (Po0.02) (Figure 2b) , whereas after the control diet the change in 2 h insulin proved insignificant (P ¼ 0.3). The between-diet difference in 2 h insulin was thus significant (P ¼ 0.015).
Changes in glucose and insulin were paralleled by observed changes in serum fructosamine (Figure 3) . Serum fructosamine concentration tended to fall (from 270.978.9 to 265.779.0 mmol/l, P ¼ 0.07) during the AX diet, but tended to rise (from 267.678.9 to 271.979.7 mmol/l, P ¼ 0.07) during the control diet. There was thus a significant between-diet difference in serum fructosamine (P ¼ 0.02).
Calculations using the above data and a ¼ 0.05 indicate that Power ¼ 0.98 for fasting glucose, 0.99 for 2 h glucose but only 0.57 for fructosamine.
No differences in outcomes relating to blood glucose, insulin and fructosamine were seen between those on medication (n ¼ 5) and those controlled by diet alone (n ¼ 10) (data not shown).
Changes in body weight, blood pressure and serum lipids Mean total body weight and fat mass remained unchanged throughout the study as did blood pressure (Table 2) . Fasting serum cholesterol, HDL-cholesterol, LDL-cholesterol and triacylglycerol concentrations were also not significantly altered by either the control or AX diets (Table 2) .
Discussion
Supplementing the diet with an 15 g/day NSP from AX-rich fibre proved effective in improving metabolic control in people with Type II diabetes. Consumption of AX-fibre was associated with significant improvement in fasting blood glucose and fructosamine concentrations, and in 2 h blood glucose and insulin concentrations. Improved glycaemic control is of importance in people with diabetes, since, if it can be sustained over the long term, it has the potential to reduce coronary heart disease risk and all-cause mortality (Wei et al, 1998) .
Study participants appeared to comply well with their diets. The majority reported that they ate all the bread and muffins supplements they were given each day. The significant increases observed in mean faecal output (P ¼ 0.05) and mean excretion of faecal polysaccharide (P ¼ 0.02) (Figure 1 ) were also consistent higher dietary fibre consumption during the AX diet. AX, a soluble, viscous fibre, would increase faecal bulk largely through promotion of increased microbial growth in the colon (Lu et al, 2000b) . Less effect on total faecal output would be expected than with an insoluble dietary fibre (Cummings, 1993) .
In the present study, dietary supplementation contributed an additional 15 g/day dietary fibre in the form of AX fibre derived from wheat. The effects of this supplement given over a period of 5 weeks to overweight people (mean BMI 28.170.9 kg/m 2 ) with Type II diabetes, confirms the suggestion advanced previously by Hanai et al (1997) that AX fibres may have the potential to improve glycaemic control. In that study, 10 g/day AX fibre derived from maize was given to three separate groups of subjects over a period of 6 months (Hanai et al, 1997) . HbA 1c levels were found to decline significantly in subjects with impaired glucose tolerance (IGT) who were also obese but not in normal weight subjects with IGT. HbA 1c levels did not decline in healthy nonobese controls. In our study, consumption of AX fibre decreased mean fasting blood glucose to 7.0 mmol/l, a concentration defining the presence or absence of hyperglycaemia (The Expert Committee on the Diagnosis and Classification of Diabetes, 1997) . The ability of AX-rich fibre to lower blood glucose appears related to its viscous, soluble nature. Other soluble fibres including guar gum (Torsdottir et al, 1991) , b-glucan (Juntunen et al, 2002) , konjac-mannan (Vuksan et al, 1999) and pysllium (Anderson et al, 1999) have similarly been found to confer metabolic benefit in people with Type II diabetes. The advantage of AX-rich fibre here lies in its high palatability (Lu et al, 2000a) . In contrast to AX-fibre, wheat bran, a typical insoluble nonviscous fibre has no apparent effect on glycaemic control. This was evident in a recent study where subjects with Type II diabetes consumed an additional 19 g of dietary fibre per day from wheat bran for 3 months without beneficial effect (Jenkins et al, 2002) .
The mechanisms by which soluble fibres influence glycaemic control are not yet well elucidated. While it has been suggested that soluble fibres may affect plasma glucose by delaying gastric emptying (Torsdottir et al, 1991) , others argue that soluble fibre exerts its effect by lowering the rate of diffusion of nutrients from the intestinal lumen to the absorptive membrane (Lund et al, 1989) or by mediating increased intestinal mobility (Cherbut et al, 1990) . The form of the food and its botanical structure can also have an important role (Juntunen et al, 2002) . Fermentation of soluble fibre within the colon produces short-chain fatty acids including proprionate and acetate. When these are absorbed, while having no direct effect on hepatic glucose production, they may act to decrease plasma nonesterified fatty acids (NEFA) (Laurent et al, 1995) . Decreased NEFA production may then affect carbohydrate metabolism and glycaemia either through the classic Randle mechanism or by improving insulin-mediated uptake of glucose into skeletal muscle (McGarry, 2002) .
Consumption of AX-rich fibre while affecting metabolic control did not affect plasma lipid concentrations (Table 2) . This differs from results obtained with other soluble dietary fibres such as those derived from oat, psyllium, guar gum or pectin. A meta-analysis of 67 controlled trials with these fibres reported a reduction of 0.045 mmol/l total cholesterol per gram soluble fibre when fibre supplementation was in the practical range of 2-10 g/day (Brown et al, 1999b) . Subjects in these studies, however, were hypercholesterolaemic with a mean total cholesterol of 6.23 mmol/l. In contrast, in the present study, subjects were normolipidaemic (mean total cholesterol 5.43 mmol/l) and had a habitual diet (before supplementation) relatively high in dietary fibre (mean intake 33 g/day) and low in total and saturated fat (26 and 11% of total energy, respectively). Therefore, before any conclusion can be drawn on the effects of AX fibre on serum lipids, further studies should be carried out in hypercholesterolaemic subjects.
Subjects were asked to consume similar amounts of food on both diets. In consequence, energy intake did not differ (8.670.1 and 8.770.1 MJ/day for control and AX diet, respectively). There was therefore no difference between diets on body weight or body fat. However, it would be of interest in further studies to determine the effects of AX fibre on acute postingestive satiety (Speechly & Buffenstein, 2000) as well as the long-term effects on body composition of diets supplemented with AX fibre and consumed ad libitum.
In conclusion, the results of this study indicate that the AX-rich fibre extracted from the by-product of wheat flour processing has beneficial effects on metabolic control in people with Type II diabetes and importantly, the products supplemented with AX fibre are palatable. AX-rich fibre has the potential for incorporation into a wide range of food products that can be used for the dietary management of Type II diabetes.
